Chronic Obstructive Pulmonary Disease: 68-Market Analysis and Sales Forecast - Update

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Chronic Obstructive Pulmonary Disease (COPD) market through 2033.

GlobalData estimated that drug sales for COPD in 2023 were approximately $11.6 billion across the 7MM. The US market makes up the majority of total global sales, contributing $8.6 billion (74.1%) due to the large COPD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the COPD market will grow to be worth approximately $30.2 billion by 2033, at a compound annual growth rate (CAGR) of 10.0% in the 7MM. The US is expected to maintain its position as the market leader in 2033, increasing the proportion of global sales it accounts for to 76.1%

Across the 68 markets, sales in the COPD market were $17.4 billion in 2023, growing to $42.2 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 66.7% and 71.5% of 68-market sales in 2023 and 2033, respectively.

Scope

• Overview of Chronic Obstructive Pulmonary Disease (COPD), including epidemiology, symptoms, diagnosis, and disease management.
• Annualized COPD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for COPD treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM as well as the 68M COPD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM COPD therapeutics market in the future. and their impact on the 68M on a macro level.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.